Doses of N-803 can be administered on an outpatient basis. Patients should be monitored for 30 minutes post dose. N-803 will not be self-administered.  Skin Rash in Association with Subcutaneous Administration of N-803 Based on current experience, localized skin rashes are common with subcutaneous administration. If a rash occurs and the rash area surrounding the N-803 injection site is > 6 cm and symptomatic (painful and/or itchy), it may be treated (at the discretion of the treating physician) with topical 0.05% clobetasol propionate (i.e. 0.05% Cormax) or 0.1% triamcinolone (i.e., Kenalog) cream. Diphenhydramine may be administered pre- (25-50 mg TID orally) and post-dosing (25-50 mg TID orally x 2 days) of N-803 at the discretion of the treating physician. Diphenhydramine should be eliminated if not tolerated. Other agents may be administered at the discretion of the treating physician. 3.2.5 Sequence and Monitoring of Dose Administration When administering concurrent investigational agents on the same day, the following sequence of administration is preferred. Acetaminophen 650 mg and Benadryl 50 mg by mouth (or another equivalent antihistamine) may be given within 30 to 60 minutes prior to M7824 infusion. Vaccines are preferred to be given within this time frame prior to M7824 infusion. Patients will be monitored for symptoms of delayed M7824 infusion reaction for 10 minutes. N-803 administration is preferred to occur after an interval of at least 10 minutes, but no longer than 5 hours, following M7824 infusion completion. 3.3 DOSE MODIFICATIONS No dose modifications are allowed. 3.3.1 Suggested evaluation of suspected bleeding or hemorrhage events and treatment modification  For anemia or hemorrhage events assessed as treatment-related, items queried may include but are not limited to detailed relevant past medical and treatment history, bruising tendency, history of blood transfusions and/or dependency, and a request for an updated participant history including details such as concomitant medications, all laboratory data, updated dosing information and recent tumor evaluation scans.  In this protocol, anemia may be due to M7824 (documented in 29% of patients) and/or SX-682. For M7824 anemia is an important identified risk (see Investigators’ Brochure). Notably, there are many reasons for hemorrhage and/or anemia in patients with advanced cancer, and Hb level of at least 10 g/dL is required for this study. A thorough investigation of new anemia cases of unspecified etiology is recommended:  Participants must enter the study with Hgb values at least 10 g/dL and baseline anemia evaluation is conducted per recommendations below.  Consider hematology consult for severe and or refractory anemias. 31 Abbreviated Title: Neoadjuvant IO for HNSCC Version Date: August 31, 2022  All relevant hematologic testing for treatment related anemias should be done prior to blood transfusion, if clinically feasible.  Transfusion should be performed at the discretion of the investigator, based on clinical assessment and considered when participant experiences significant anemia.